Calendar |
|
|
|
|
Highlights of ASH ® in North America
January 13 – 14 , 2017 Atlanta , GA
January 20 – 21 , 2017 Chicago , IL Dallas , TX
January 27 – 28 , 2017 New York , NY Seattle , WA
|
American Association for Cancer Research Annual Meeting
April 1 – 5 , 2017 Washington , DC The American Association for Cancer Research Annual Meeting highlights cancer science and medicine from institutions all over the world . The focus of this year ’ s meeting is addressing disparities in cancer research .
|
Anticoagulation Forum ’ s 14th National Conference on Anticoagulant Therapy
April 20 – 22 , 2017 Los Angeles , CA The Anticoagulation Forum ’ s 14th National Conference on Anticoagulant Therapy offers attendees the unique opportunity to meet colleagues from around the world with wide-ranging research interests and expertise in the diagnosis and treatment of thrombotic disorders .
|
|
Oncology Nursing Society Annual Congress
May 4 – 7 , 2017 Denver , CO The 41st Oncology Nursing Society Congress will feature educational opportunities , patient resources , and clinical practice information through sessions led by oncology nursing professionals .
|
|
Highlights of ASH ® Asia - Pacific
March 10 – 12 , 2017 Hong Kong
|
|
|
|
Highlights of ASH ® Latin America
April 7 – 8 , 2017 Punta del Este , Uruguay
BOSULIF is indicated for the treatment of adult patients with chronic , accelerated , or blast phase Philadelphia chromosome – positive ( Ph +) chronic myelogenous leukemia ( CML ) with resistance or intolerance to prior therapy .
American Academy of Hospice and Palliative Medicine Annual Assembly
February 22 – 25 , 2017 Phoenix , AZ This educational event brings together physicians , nurses , and other health-care providers to share research , clinical best practices , and practice-related guidance to improve quality of life for patients and families facing serious or life-threatening conditions .
16th International Myeloma Workshop
March 1 – 4 , 2017 New Delhi , India During this bi-annual event , myeloma experts from around the world gather to discuss basic , preclinical , and clinical aspects in the biology and treatment of multiple myeloma . The scientific program will include oral presentations , consensus panels , debates on controversial and current arguments , and poster abstracts .
In the treatment of adult patients with Ph + CML with resistance or intolerance to prior therapy
Everyone has a distinct profile
Consider your patient . Consider BOSULIF .
( bosutinib )
Bosutinib ( BOSULIF ®) is recommended by the NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ®) as a treatment option for patients with CML in need of 2nd- or later-line TKI therapy . 1
Study design : BOSULIF 500 mg once-daily treatment was studied in a single-arm , Phase 1 / 2 , open-label , multicenter trial ( N = 546 ) in patients with CP , AP , or BP CML in second line ( after imatinib ) or in third line ( after imatinib followed by dasatinib and / or nilotinib ). Of the 546 patients enrolled , 73 % were imatinib resistant and 27 % were imatinib intolerant . 2
AP = accelerated phase ; BP = blast phase ; CP = chronic phase .
Diwan-i-Am at the Red Fort in Delhi , India
National Comprehensive Cancer Network Annual Conference
March 23 – 25 , 2017 Orlando , FL More than 1,600 health-care professionals involved in the care of patients with cancer are expected to attend the National Comprehensive Cancer Network ’ s 22nd Annual Conference to discuss the theme : “ Improving the Quality , Effectiveness , and Efficiency of Cancer Care .”
IMPORTANT SAFETY INFORMATION
Contraindication : History of hypersensitivity to BOSULIF . Reactions have included anaphylaxis . Anaphylactic shock occurred in less than 0.2 % of treated patients in clinical trials .
Gastrointestinal Toxicity : Diarrhea , nausea , vomiting , and abdominal pain can occur . In the clinical trial , median time to onset for diarrhea was 2 days , median duration was 1 day , and median number of episodes per patient was 3 ( range 1-221 ). Monitor and manage patients using standards of care , including antidiarrheals , antiemetics , and / or fluid replacement . Withhold , dose reduce , or discontinue BOSULIF as necessary .
Myelosuppression : Thrombocytopenia , anemia , and neutropenia can occur . Perform complete blood counts weekly for the first month and then monthly or as clinically indicated . Withhold , dose reduce , or discontinue BOSULIF as necessary .
Hepatic Toxicity : Twenty percent of patients experienced an increase in either ALT or AST . Liver enzyme elevation usually occurs early in treatment . Perform hepatic enzyme tests monthly for the first 3 months and as clinically indicated . In patients with transaminase elevations , monitor liver enzymes more frequently . Drug-induced liver injury has occurred . Withhold , dose reduce , or discontinue BOSULIF as necessary . In patients with mild , moderate , or severe hepatic impairment , the recommended starting dose is 200 mg daily .
Renal Toxicity : An on-treatment decline in estimated glomerular filtration rate has occurred in patients treated with BOSULIF . Monitor renal function at baseline and during therapy , with particular attention to patients with preexisting renal impairment or risk factors . Consider dose adjustment in patients with baseline and treatment emergent renal impairment . The recommended starting doses for patients with severe renal impairment ( CrCL < 30 mL / min ) or moderate renal impairment ( CrCL 30-50 mL / min ) are 300 mg and 400 mg daily , respectively .
Fluid Retention : Fluid retention can occur and may cause pericardial effusion , pleural effusion , pulmonary edema , and / or peripheral edema . Monitor and manage patients using standards of care . Interrupt , dose reduce , or discontinue BOSULIF as necessary .